The future of obesity care and the GLP-1 phenomenon

Over a billion people globally are living with obesity, but its status as a ‘disease’ and available solutions have often been contentious.When the market for obesity drugs is projected to hit $100 billion by 2030, what will be the impact for patients, payers, healthcare professionals, and industries beyond healthcare?Listen to Melissa Moodley and Dr. Stuart W. Flint, Associate Professor at the University of Leeds, as they explore some of the trends and latest views on obesity treatment, such as the onus on patients to manage their own obesity, the possibility of preventative care, government focus and the effect of celebrity on GLP-1 uptake.